PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24215511-0	2013	Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.	gemcitabine	120-131	ribonucleotide reductase catalytic subunit M1	Homo sapiens	20-24	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	gemcitabine	224-235	ribonucleotide reductase catalytic subunit M1	Homo sapiens	131-166	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	gemcitabine	224-235	ribonucleotide reductase catalytic subunit M1	Homo sapiens	168-172